Semaglutide is a glucagon-like peptide-1 receptor agonist that was recently approved by the
US Food and Drug Administration for chronic weight management. This paper reviews data …

Abstract Losses of 5–10% or more of initial body weight are associated with improvements
in obesity-related comorbidities. However, attaining and sustaining this level of weight loss …

Obesity is a chronic, relapsing disease associated with multiple complications and a
substantial morbidity, mortality and health care burden. Pharmacological treatments for …

What is known and objective The purpose of this review paper is to review the efficacy and
safety of subcutaneous semaglutide, marketed as Wegovy, a glucagon‐like peptide‐1 …

Semaglutide is a glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) with a long
elimination half‐life, allowing subcutaneous (sc) administration once per week. Both the …

Obesity is a chronic disease associated with serious complications and increased mortality.
Weight loss (WL) through lifestyle changes results in modest WL long-term possibly due to …

In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major
adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease …

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) came to market in the year 2005, as
a new therapeutic classification, for clinical use in the management of type 2 diabetes …

Aims Evaluate the effects of once‐weekly subcutaneous semaglutide 2.4 mg on
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …